Page 104 - 南京医科大学学报自然科学版
P. 104

第42卷第7期
               ·1000 ·                           南 京    医 科 大 学 学         报                        2022年7月


                   cal outcomes after cytoreductive nephrectomy with inferi⁃  2010,9(1/2/3/4/5/6):461-473
                   or vena cava thrombectomy[J]. Urology,2014,84(6):  [15] MATTEI J,DA SILVA R D,SEHRT D,et al. Targeted

                   1414-1419                                         therapy in metastatic renal carcinoma[J]. Cancer Lett,
             [12] BELLDEGRUN A S,KLATTE T,SHUCH B,et al. Cancer⁃     2014,343(2):156-160
                   specific survival outcomes among patients treated during  [16] 田  野,王尚乾,苗陈岿,等. 晚期肾癌免疫检查点治疗
                   the cytokine era of kidney cancer(1989-2005):a bench⁃  新进展[J]. 南京医科大学学报(自然科学版),2019,39
                   mark for emerging targeted cancer therapies[J]. Cancer,  (1):153-157
                   2008,113(9):2457-2463                        [17] YOON Y E,LEE H H,KIM K H,et al. Focal therapy ver⁃
             [13] MCDERMOTT D F,REGAN M M,CLARK J I,et al. Ran⁃      sus robot ⁃ assisted partial nephrectomy in the manage⁃
                   domized phase Ⅲ trial of high⁃dose interleukin⁃2 versus  ment of clinical T1 renal masses:a systematic review and
                   subcutaneous interleukin⁃2 and interferon in patients with  meta⁃analysis[J]. Medicine(Baltimore),2018,97(45):
                   metastatic renal cell carcinoma[J]. J Clin Oncol,2005,23  e13102
                  (1):133-141                                                             [收稿日期] 2022-01-25
             [14] CAIRNS P. Renal cell carcinoma[J]. Cancer Biomark,                           (责任编辑:蒋      莉)





              

              (上接第912页)



                   down reverses multidrug resistance of human myeloge⁃  [22] BERETTA G L,BENEDETTI V,COSSA G,et al. In⁃
                   nous leukemia K562/ADM cells by downregulating P⁃gp,  creased levels and defective glycosylation of MRPs in
                   MRP1 and BCRP expression via PI3K/Akt signaling path⁃  ovarian carcinoma cells resistant to oxaliplatin [J].Bio⁃
                   way[J]. Int J Oncol,2016,49(6):2529-2537          chem Pharmacol,2010,79(8):1108-1117
             [20] GAO R,FANG C,XU J,et al. LncRNA CACS15 contrib⁃  [23] ZAREI S,REZA J Z,JALIANI H Z,et al. Effects of carfil⁃
                   utes to oxaliplatin resistance in colorectal cancer by posi⁃  zomib alone and in combination with cisplatin on the cell
                   tively regulating ABCC1 through sponging miR⁃145[J].  death in cisplatin⁃sensitive and cisplatin⁃resistant ovarian
                   Arch Biochem Biophys,2019,663:183-191             carcinoma cell lines[J]. Bratisl Lek Listy,2019,120(6):
             [21] 杨    军 ,彭   梅. 上 皮 性 卵 巢 癌 中 MRP1、BCRP、            468-475
                   BRCA1基因的表达及其意义[J]. 实用医院临床杂志,                                           [收稿日期] 2022-01-20
                   2018,15(4):9-12                                                             (本文编辑:蒋 莉)
   99   100   101   102   103   104   105   106   107   108   109